← Back

Ocular Therapeutix Inc

Ocular Therapeutix, Inc. is a biopharmaceutical company that develops and commercializes therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert for post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel in phase 3 clinical trials for wet age-related macular degeneration and non-proliferative diabetic retinopathy, and OTX-TIC, a travoprost intracameral hydrogel that has completed phase 2 clinical trials for open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Country
Price · split & dividend adjusted
News & notes moving OCUL
OCUL

Ocular Therapeutix Grants Inducement Awards to Eleven New Employees

Ocular Therapeutix has granted inducement equity awards to eleven newly hired non-executive employees. The awards, effective July 6, 2026, consist of stock options to purchase up to 34,700 shares and restricted stock units for 11,375 shares. The options have an exercise price of $9.66 per share, a ten-year term, and vest over four years. The restricted stock units vest over three years in equal annual installments. The grants were made under the company's 2019 Inducement Stock Incentive Plan as required by Nasdaq Listing Rule 5635(c)(4).
OCUL
GlobeNewswire·71dRead more →
OCUL▲

Ocular Therapeutix to Present at July Scientific and Investor Conferences

Ocular Therapeutix announced its participation in several scientific and investor conferences in July 2026. At the OIS Retina Innovation Summit on July 14, Chief Development Officer Peter K. Kaiser will present on the company's retina experience, and Executive Chairman, President and CEO Pravin U. Dugel will moderate a panel on FDA guidance. At the ASRS 44th Annual Meeting from July 15 to 18, the company will present Phase 3 SOL-1 trial results for its investigational axitinib hydrogel OTX-TKI in wet AMD, along with real-world anti-VEGF treatment analyses and a symposium on redefining nAMD management. Additionally, Dugel will participate in a fireside chat at the HC Wainwright 6th Annual Ophthalmology Virtual Conference on July 22.
OCUL ▲
GlobeNewswire·79dRead more →
OCUL▼

Ocular Therapeutix Shares Fall 18.5% Over Six Months Amid Revenue Declines and Deepening Losses

Ocular Therapeutix shares have dropped 18.5% over the past six months to $10.37, underperforming the S&P 500's 7.8% gain. The company's revenue has declined at an annualized rate of 6.7% over the last two years, while its adjusted operating margin and free cash flow margin for the trailing 12 months stand at negative 575% and negative 463%, respectively. StockStory analysts cite these deteriorating fundamentals as reasons to avoid the stock, noting that the market expects continued losses and that the forward price-to-sales ratio of 42.4 times offers limited upside relative to the potential downside.
OCUL ▼
StockStory·86dRead more →
OCUL▲2

Ocular Therapeutix Plans AXPAXLI NDA Submission for Wet AMD in Late 2026

Ocular Therapeutix announced FDA alignment on its new drug application for AXPAXLI in wet age-related macular degeneration during an investor day event. The company reached agreement with the FDA to include safety data from the Phase 3 SOL-R trial in the NDA submission while excluding its efficacy data, following a Type C meeting. A pre-NDA meeting is expected in the third quarter of 2026, with a complete NDA package submission anticipated in the fourth quarter alongside an interim safety analysis for SOL-R. If approved, AXPAXLI could launch in 2027, with topline SOL-R efficacy data planned for early 2028. The drug is also being studied in diabetic retinopathy in the HELIOS-3 registrational trial.
OCUL ▲
RTTNews·89dRead more →
© 2026 MarketDXAsset